Farampator

Drug Profile

Farampator

Alternative Names: CX 691; ORG 24448

Latest Information Update: 18 Dec 2008

Price : $50

At a glance

  • Originator Cortex Pharmaceuticals; University of California at Irvine
  • Developer Organon
  • Class Antidepressants; Antipsychotics; Neuroprotectants; Nootropics; Oxadiazoles; Piperidines; Small molecules
  • Mechanism of Action AMPA receptor agonists; Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Major depressive disorder; Schizophrenia

Most Recent Events

  • 19 Nov 2007 Organon has been acquired by Schering-Plough
  • 17 Oct 2007 Final efficacy data from a clinical trial in healthy elderly volunteers presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
  • 17 Jan 2001 Phase-I clinical trials for Psychotic disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top